Skip to main content
. Author manuscript; available in PMC: 2015 Jan 11.
Published in final edited form as: Gynecol Oncol. 2010 Sep 6;119(3):564–570. doi: 10.1016/j.ygyno.2010.07.037

Fig. 5.

Fig. 5

(A) The tumor volume resulting from subcutaneous inoculation of SKOV-3 cells in athymic female nu/nu mice treated with mouse monoclonal anti-hVEGF antibody, rabbit polyclonal anti-MVF-VEGF(102-122) antibodies or anti-MVF-VEGF(127-144) antibodies was significantly smaller compared to PBS control mice from 11 days after inoculation, p<0.01). There is no difference in tumor volume between mice treated with normal rabbit IgG and mice of PBS control (p>0.05). (B) Immunostaining for endothelial cells (CD31) demonstrated reduced microvessel density in tumors from mice treated with mouse monoclonal anti-hVEGF antibody, rabbit polyclonal anti-MVFVEGF(102-122) antibodies or anti-MVF-VEGF(127-144) antibodies is significantly lower than that of mice treated with PBS (p<0.01). There is no difference in tumor microvessel density between mice treated with normal rabbit IgG and mice treated with PBS (p>0.05).